Legal & General Group Plc Grows Holdings in Achillion Pharmaceuticals, Inc. (ACHN)

Legal & General Group Plc boosted its holdings in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 53.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 42,900 shares of the biopharmaceutical company’s stock after purchasing an additional 15,000 shares during the quarter. Legal & General Group Plc’s holdings in Achillion Pharmaceuticals were worth $196,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the business. Schwab Charles Investment Management Inc. boosted its holdings in Achillion Pharmaceuticals by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 457,341 shares of the biopharmaceutical company’s stock worth $2,100,000 after purchasing an additional 2,850 shares during the period. Bank of Montreal Can boosted its holdings in Achillion Pharmaceuticals by 6.4% in the second quarter. Bank of Montreal Can now owns 56,715 shares of the biopharmaceutical company’s stock worth $260,000 after purchasing an additional 3,410 shares during the period. SG Americas Securities LLC boosted its holdings in Achillion Pharmaceuticals by 18.6% in the second quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 4,144 shares during the period. American International Group Inc. boosted its holdings in Achillion Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 72,153 shares of the biopharmaceutical company’s stock worth $304,000 after purchasing an additional 4,771 shares during the period. Finally, Alps Advisors Inc. boosted its holdings in Achillion Pharmaceuticals by 5.0% in the second quarter. Alps Advisors Inc. now owns 123,412 shares of the biopharmaceutical company’s stock worth $566,000 after purchasing an additional 5,824 shares during the period. 74.11% of the stock is owned by hedge funds and other institutional investors.

Achillion Pharmaceuticals, Inc. (NASDAQ ACHN) opened at 4.59 on Friday. The stock’s 50 day moving average is $4.47 and its 200 day moving average is $4.25. Achillion Pharmaceuticals, Inc. has a one year low of $3.15 and a one year high of $7.34. The firm’s market cap is $627.73 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.16). During the same period in the prior year, the firm earned ($0.14) earnings per share. On average, equities research analysts expect that Achillion Pharmaceuticals, Inc. will post ($0.66) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Legal & General Group Plc Grows Holdings in Achillion Pharmaceuticals, Inc. (ACHN)” was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.themarketsdaily.com/2017/10/13/legal-general-group-plc-grows-holdings-in-achillion-pharmaceuticals-inc-achn.html.

ACHN has been the subject of several analyst reports. Ladenburg Thalmann Financial Services reduced their price target on shares of Achillion Pharmaceuticals from $9.00 to $6.50 and set a “buy” rating for the company in a report on Tuesday, September 12th. Zacks Investment Research raised shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, September 14th. BidaskClub downgraded shares of Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. Chardan Capital reduced their price target on shares of Achillion Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating for the company in a report on Wednesday, August 9th. Finally, Robert W. Baird reissued a “neutral” rating and set a $4.00 price target (down previously from $5.00) on shares of Achillion Pharmaceuticals in a report on Tuesday, September 12th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. Achillion Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $6.75.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply